Hillsdale Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,210
| Closed | -$576K | – | 629 |
|
|
2025
Q1 | $576K | Sell |
4,210
-400
| -9% | -$57.2K | 0.03% | 345 |
|
|
2024
Q4 | $705K | Buy |
+4,610
| New | +$778K | 0.04% | 316 |
|
|
2023
Q1 | – | Sell |
-1,790
| Closed | -$496K | – | 570 |
|
|
2022
Q4 | $496K | Hold |
1,790
| – | – | 0.04% | 344 |
|
|
2022
Q3 | $478K | Hold |
1,790
| – | – | 0.04% | 336 |
|
|
2022
Q2 | $365K | Buy |
1,790
+100
| +6% | +$20.4K | 0.03% | 385 |
|
|
2022
Q1 | $356K | Hold |
1,690
| – | – | 0.02% | 390 |
|
|
2021
Q4 | $406K | Hold |
1,690
| – | – | 0.03% | 387 |
|
|
2021
Q3 | $478K | Buy |
1,690
+40
| +2% | +$13.1K | 0.04% | 394 |
|
|
2021
Q2 | $571K | Buy |
+1,650
| New | +$500K | 0.05% | 362 |
|
|
2021
Q1 | – | Sell |
-1,823
| Closed | -$446K | – | 544 |
|
|
2020
Q4 | $446K | Hold |
1,823
| – | – | 0.04% | 365 |
|
|
2020
Q3 | $518K | Hold |
1,823
| – | – | 0.05% | 311 |
|
|
2020
Q2 | $487K | Buy |
1,823
+50
| +3% | +$15K | 0.04% | 324 |
|
|
2020
Q1 | $561K | Sell |
1,773
-12
| -0.7% | -$3.64K | 0.07% | 271 |
|
|
2019
Q4 | $529K | Buy |
1,785
+50
| +3% | +$13.9K | 0.05% | 333 |
|
|
2019
Q3 | $404K | Buy |
1,735
+20
| +1% | +$4.66K | 0.04% | 388 |
|
|
2019
Q2 | $402K | Buy |
1,715
+300
| +21% | +$69.3K | 0.04% | 378 |
|
|
2019
Q1 | $335K | Hold |
1,415
| – | – | 0.03% | 372 |
|
|
2018
Q4 | $426K | Hold |
1,415
| – | – | 0.05% | 296 |
|
|
2018
Q3 | $500K | Hold |
1,415
| – | – | 0.07% | 174 |
|
|
2018
Q2 | $410K | Sell |
1,415
-5
| -0.4% | -$1.41K | 0.05% | 228 |
|
|
2018
Q1 | $389K | Hold |
1,420
| – | – | 0.05% | 223 |
|
|
2017
Q4 | $452K | Hold |
1,420
| – | – | 0.07% | 212 |
|
|
2017
Q3 | $445K | Buy |
1,420
+200
| +16% | +$59.2K | 0.08% | 198 |
|
|
2017
Q2 | $330K | Sell |
1,220
-110
| -8% | -$29.1K | 0.06% | 228 |
|
|
2017
Q1 | $364K | Hold |
1,330
| – | – | 0.07% | 205 |
|
|
2016
Q4 | $378K | Sell |
1,330
-200
| -13% | -$59.3K | 0.08% | 185 |
|
|
2016
Q3 | $479K | Hold |
1,530
| – | – | 0.13% | 148 |
|
|
2016
Q2 | $369K | Buy |
1,530
+100
| +7% | +$26.4K | 0.11% | 198 |
|
|
2016
Q1 | $372K | Buy |
1,430
+100
| +8% | +$26.4K | 0.13% | 187 |
|
|
2015
Q4 | $407K | Buy |
1,330
+400
| +43% | +$115K | 0.15% | 130 |
|
|
2015
Q3 | $271K | Hold |
930
| – | – | 0.09% | 235 |
|
|
2015
Q2 | $376K | Sell |
930
-100
| -10% | -$40.1K | 0.11% | 167 |
|
|
2015
Q1 | $435K | Sell |
1,030
-150
| -13% | -$59.1K | 0.11% | 148 |
|
|
2014
Q4 | $401K | Hold |
1,180
| – | – | 0.1% | 152 |
|
|
2014
Q3 | $390K | Hold |
1,180
| – | – | 0.12% | 119 |
|
|
2014
Q2 | $372K | Sell |
1,180
-50
| -4% | -$15K | 0.08% | 153 |
|
|
2014
Q1 | $376K | Buy |
1,230
+200
| +19% | +$63.5K | 0.11% | 128 |
|
|
2013
Q4 | $288K | Sell |
1,030
-300
| -23% | -$77.6K | 0.08% | 218 |
|
|
2013
Q3 | $320K | Hold |
1,330
| – | – | 0.1% | 171 |
|
|
2013
Q2 | $286K | Buy |
+1,330
| New | +$284K | 0.09% | 195 |
|
Other funds holding BIIB
Hillsdale Investment Management's BIIB Position: Q2 2025 in Review
Hillsdale Investment Management sold out of Biogen (BIIB) in Q2 2025, closing a stake of 4,210 shares — an estimated $576K sold.
Hillsdale Investment Management first reported a position in BIIB in Q2 2013 and held it in 40 quarters. The position peaked at $705K in Q4 2024. 867 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.
- Hillsdale Investment Management reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
- Hillsdale Investment Management sold 4,210 Biogen shares in Q2 2025, an estimated $576K.
- Hillsdale Investment Management first reported a position in Biogen in Q2 2013 and held it in 40 quarters.
- Hillsdale Investment Management's Biogen position peaked at $705K in Q4 2024.
- 867 funds tracked by Wall St. Rank held Biogen as of Q2 2025.
Based on Hillsdale Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.